AT7519
Code | Size | Price |
---|
TAR-T6205-5mg | 5mg | £112.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6205-1mL | 1 mL * 10 mM (in DMSO) | £114.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6205-10mg | 10mg | £134.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6205-25mg | 25mg | £161.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6205-50mg | 50mg | £206.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6205-100mg | 100mg | £251.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
CAS:
844442-38-2
Formula:
C16H17Cl2N5O2
Molecular Weight:
382.25
Pathway:
PI3K/Akt/mTOR signaling; Apoptosis; Cell Cycle/Checkpoint; Stem Cells
Purity:
0.9967
SMILES:
Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1
Target:
Apoptosis; GSK-3; CDK
References
Zhao W, Zhang L, Zhang Y, et al.The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest.Cell Death & Disease.2023, 14(1): 11.
Kazi A, Chen L, Xiang S, et al. Global Phosphoproteomics reveal CDK suppression as a vulnerability to KRAS addiction in Pancreatic Cancer. Clinical Cancer Research. 2021 Jul 15;27(14):4012-4024. doi: 10.1158/1078-0432.CCR-20-4781. Epub 2021 Apr 20.
Kazi A, Chen L, Xiang S, et al. Global Phosphoproteomics reveal CDK suppression as a vulnerability to KRAS addiction in Pancreatic Cancer[J]. Clinical Cancer Research. 2021
Santo L, et al. Oncogene, 2010, 29(16), 2325-2336.
Squires MS, et al. Mol Cancer Ther, 2009, 8(2), 324-332.